Concepta (LON:CPT)

Concepta (LON:CPT)


Share Price
3.32 p
Change
-0.18 (-5.14 %)
Market Cap
£8.80 m
Proactive Investors - Run By Investors For Investors

Concepta RNS Release

Result of Meeting


RNS Number : 1085X
Concepta PLC
25 April 2019
 

 

25 April 2019

Concepta plc

Result of Meeting

At the general meeting of the Company held earlier today, all the resolutions were passed by shareholders. The 76,750,000 new ordinary shares of 2.5 pence per share ("Ordinary Shares") issued in the placing at 3 pence per share, as announced on 8 April 2019, are expected to be admitted to trading at 8.00 a.m. on 26 April 2019.

The Group will issue its 2018 Financial Year preliminary results announcement on 14th May 2019.

Enquiries

Company: www.conceptaplc.com, Product: www.mylotus.com

Matthew Walls, Chairman

Tel: +44 (0) 1234 866601

SPARK Advisory Partners Limited (Nominated Adviser)

Neil Baldwin

Tel: +44 (0)20 368 3550

Novum Securities

Colin Rowbury

+44 (0) 20 7399 9400

About Concepta Plc:

Concepta Plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalised mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.

myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception

rates and early diagnosis of fertility issues. The proposition of myLotus® is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.

The Company has received CE-mark certification for myLotus® and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2019.

myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ROMIAMMTMBMTBAL

Concepta Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use